MIST

Milestone Pharmaceuticals Inc. (MIST) ESG Analysis Analysis (2026)

Invetso Score: 4.9/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 4.5 (Moderate)

Milestone’s environmental risks are inherently limited by its business model, but the absence of formal sustainability policies or disclosures places it below sector leaders on environmental transparency and proactive management.

Social

Score:

Milestone demonstrates a clear social mission and responsible clinical practices, but financial constraints and high reliance on equity-based compensation may limit its ability to sustain and scale positive social outcomes relative to larger, more established peers.

Governance

Score:

Milestone’s governance practices meet basic compliance and transparency standards, but financial risk and limited ESG-specific disclosures constrain its governance score relative to best-in-class biopharma peers.

Overall Score

Score:

Milestone Pharmaceuticals demonstrates moderate ESG performance, with limited environmental risk, a strong social mission, and basic governance compliance. However, the absence of formal ESG policies, persistent financial losses, and limited transparency on sustainability and risk management keep its overall ESG profile below sector leaders.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Milestone Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →